Kamil Gotfryd

Kamil Gotfryd


Aktuel forskning

Paragraph about dissertation aims:

Valproic acid (VPA) is a widely used anti-epileptic drug, which is also used for the treatment of e.g. bipolar disorder, migraine and neuropathic pain. Moreover, VPA has been proposed for the treatment of certain types of cancer because of its effects on cell growth, differentiation, motility and survival. However, recent studies have shown cell type-specific effects of VPA, with regard to modulation of cellular and intracellular processes by the drug. The aims of the Ph.D. project are to study the effects of VPA on cancer-related cellular processes such as cell motility, growth and differentiation as well as to investigate the effects of VPA on selected intracellular events, including the modulation of the Erk1/2 activities and inhibition of histone deacetylases. The second part of the project is devoted to the investigations of the biological effects of the two VPA derivatives - enantiomers of pentyl-4-pentynoic acid, with an emphasis on their anti-cancer, neuroprotective and memory and learning-related potentials.

List of recent/selected publications:

Ambjørn, M., Asmussen, J.W., Lindstam, M., Gotfryd, K., Jacobsen, C., Kiselyov, V.V., Moestrup, S.K., Penkowa, M., Bock, E., Berezin, V., 2008. Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. J Neurochem, 104, 21-37.

Gotfryd, K., Owczarek, S., Hoffmann, K., Klementiev, B., Nau, H., Berezin, V., Bock, E., Walmod, P.S., 2007. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology, 52, 764-778.

ID: 5885